Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
EClinicalMedicine,
Год журнала:
2024,
Номер
71, С. 102553 - 102553
Опубликована: Март 18, 2024
BackgroundThe
COVID-19
pandemic
heightened
risks
for
individuals
with
hematological
malignancies
due
to
compromised
immune
systems,
leading
more
severe
outcomes
and
increased
mortality.
While
interventions
like
vaccines,
targeted
antivirals,
monoclonal
antibodies
have
been
effective
the
general
population,
their
benefits
these
patients
may
not
be
as
pronounced.MethodsThe
EPICOVIDEHA
registry
(National
Clinical
Trials
Identifier,
NCT04733729)
gathers
data
from
malignancy
since
pandemic's
start
worldwide.
It
spans
various
global
locations,
allowing
comprehensive
analysis
over
first
three
years
(2020–2022).FindingsThe
collected
January
2020
December
2022,
involving
8767
cases
in
152
centers
across
41
countries,
42%
being
female.
Over
this
period,
there
was
a
significant
reduction
critical
infections
an
overall
decrease
mortality
29%
4%.
However,
hospitalization,
particularly
ICU,
remained
associated
higher
rates.
Factors
contributing
included
age,
multiple
comorbidities,
active
at
onset,
pulmonary
symptoms,
hospitalization.
On
positive
side,
vaccination
one
two
doses
or
doses,
well
encountering
were
improved
survival.InterpretationPatients
still
face
elevated
risks,
despite
reductions
rates
time.
Hospitalization,
especially
ICUs,
remains
concern.
The
study
underscores
importance
of
timing
exposure
2022
enhanced
survival
patient
group.
Ongoing
monitoring
are
essential
support
vulnerable
emphasizing
role
timely
diagnosis
prompt
treatment
preventing
cases.FundingNot
applicable.
Язык: Английский
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Clinical and Experimental Medicine,
Год журнала:
2024,
Номер
24(1)
Опубликована: Июнь 4, 2024
Abstract
Patients
with
hematologic
malignancies
(HMs)
are
at
a
significantly
higher
risk
of
contracting
COVID-19
and
experiencing
severe
outcomes
compared
to
individuals
without
HMs.
This
heightened
is
influenced
by
various
factors,
including
the
underlying
malignancy,
immunosuppressive
treatments,
patient-related
factors.
Notably,
regimens
commonly
used
for
HM
treatment
can
lead
depletion
B
cells
T
cells,
which
associated
increased
COVID-19-related
complications
mortality
in
these
patients.
As
pandemic
transitions
into
an
endemic
state,
it
remains
crucial
acknowledge
address
ongoing
In
this
review,
we
aim
summarize
current
evidence
enhance
our
understanding
impact
HMs
on
risks
outcomes,
identify
particularly
vulnerable
individuals,
emphasize
need
specialized
clinical
attention
management.
Furthermore,
impaired
immune
response
vaccination
observed
patients
underscores
importance
implementing
additional
mitigation
strategies.
may
include
targeted
prophylaxis
antivirals
monoclonal
antibodies
as
indicated.
To
provide
practical
guidance
considerations,
present
two
illustrative
cases
highlight
real-life
challenges
faced
physicians
caring
HMs,
emphasizing
individualized
management
based
disease
severity,
type,
unique
circumstances
each
patient.
Язык: Английский
S1-Leitlinie Nachhaltigkeit in der Intensiv- und Notfallmedizin
Medizinische Klinik - Intensivmedizin und Notfallmedizin,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 24, 2025
Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024
Blood Research,
Год журнала:
2025,
Номер
60(1)
Опубликована: Март 28, 2025
Abstract
Introduction
COVID-19
remains
a
major
threat
to
immunocompromised
individuals.
The
determination
of
circulating
SARS-CoV-2
antibodies
in
patients
at
high
risk
for
severe
course
infection
is
important
estimating
the
vaccine-induced
humoral
immune
response.
Therefore,
we
assessed
status
quo
after
winter
analyze
need
booster
vaccinations.
Methods
Anti-spike
IgG
levels
46
hospitalized
with
hematological
and
oncological
diseases,
measured
between
21th
December
2023
8th
February
2024,
were
compared
subgroups
patients.
Demographic
data,
underlying
antineoplastic
treatment,
number
positive
tests
University
Hospital
Cologne
collected.
Results
Patients
different
diseases
showed
varying
spike
antibody
levels.
highest
found
diffuse
large
cell
B-cell
lymphoma
(DLBCL)
acute
leukemia
who
had
not
received
specific
treatment
or
just
initiated
whereas
lowest
DLBCL,
leukemia,
multiple
myeloma
least
one
line
treatment.
geometric
mean
titers
higher
female
than
male
aged
41–50
years
while
those
61–70
years.
Conclusion
data
presented
confirm
broad
variations
anti-spike
across
highlight
complex
interference
cancer
biology,
dysfunction,
treatment-related
factors
shaping
responses.
Further
research
needed
elucidate
mechanisms
these
We
emphasize
regular
vaccinations
this
patient
group.
Язык: Английский
New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups
Immunity Inflammation and Disease,
Год журнала:
2024,
Номер
12(6)
Опубликована: Июнь 1, 2024
The
COVID-19
pandemic
has
taken
many
forms
and
continues
to
evolve,
now
around
the
Omicron
wave,
raising
concerns
over
globe.
With
being
declared
no
longer
a
"public
health
emergency
of
international
concern
(PHEIC),"
COVID
is
still
far
from
over,
as
new
subvariants
interest
have
risen
since
January
2023.
Mainly
with
XBB.1.5
XBB.1.16
subvariants,
very
much
"alive"
"breathing."
Язык: Английский
Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination
European Journal Of Haematology,
Год журнала:
2023,
Номер
111(4), С. 668 - 670
Опубликована: Июль 18, 2023
Язык: Английский
COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period
TURKISH JOURNAL OF MEDICAL SCIENCES,
Год журнала:
2023,
Номер
53(6), С. 1744 - 1755
Опубликована: Дек. 12, 2023
Background/aim:It
wasaimed
herein
to
investigate
coronavirus
disease
(COVID-19)
in
cancer
patients
and
compare
hematological
solid
organ
terms
of
the
course
outcome
this
disease.
Materials
methods:Data
from
with
laboratory-confirmed
COVID-19
infection
were
analyzed
retrospectively.
Risk
factors
for
poor
prognosis
effect
vaccination
on
clinical
outcomes
evaluated.
Results:A
total
403
who
diagnosed
between
March
1st,
2021,
November
30th,
2022,
included,
whom
329
(81.6%)
had
74
(18.4%)
cancers.
Hospitalization
intensive
care
unit
(ICU)
admission
rates
significantly
higher
compared
(73.0%
vs.
35.9%,
p<
0.001
25.7%
14.0%,
p=
0.013,
respectively).
The
COVID-19-related
case
fatality
rate
(CFR)
was
defined
as
15.4%,
it
hematologicalcancer
patientsthan
inthe
(23.0%
13.7%,
0.045)
metastatic/advanced
other
stages
(p<
0.001).
In
cancergroup,
hospitalization,
ICU
admission,
CFR
respiratory
genitourinary
cancers
A
288
(71.8%)
receivedCOVID-19
vaccination;
164
(56.94%)
had≤2
doses
124
(43.06%)
had≥3
doses.The
hospitalization
≤2
vaccine
those
≥3
(48.2%
29.8%,p=
0.002).
Patients
COVID-19-
related
death
levels
leucocyte,
neutrophil,
D-dimer,
troponin,
C-reactive
protein
(CRP),
procalcitonin,
ferritin
lower
lymphocyte
than
survivors.
logistic
regression
analysis,the
risk
mortality
patients(OR:1.726),
male
(OR:1.757),
Pre-Delta/Delta
variants
(OR:1.817).
Conclusion:This
study
revealed
that
there
is
an
increased
serious
events
(hospitalization,
or
death)
cancerscompared
have
It
wasalso
show
cine
more
protective
against
severe
illness
need
doses.
Язык: Английский
Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(24), С. 13613 - 13613
Опубликована: Дек. 19, 2024
This
longitudinal
study
examined
how
active
gastrointestinal
(GI)
cancer
types
affect
immune
responses
to
SARS-CoV-2,
focusing
on
the
ability
neutralize
Omicron
variants.
Patients
with
GI
(n
=
168)
were
categorized
into
those
hepatocellular
carcinoma,
hepatic
metastatic
cancer,
non-hepatic
and
two
control
groups
of
patients
without
underlying
liver
diseases.
Humoral
cellular
evaluated
before
after
antigen
exposures.
In
pre-Omicron
era,
humoral
SARS-CoV-2
immunity
decreased
three
contacts
further
exposure.
While
neutralization
was
significantly
lower
than
wildtype
(p
<
0.01),
infections
yet
mild
moderate.
Additional
exposures
improved
IgG
levels
0.01)
0.01).
However,
this
effect
less
intense
in
particularly
pancreaticobiliary
neoplasms
(PBN;
p
0.04),
immunodeficiency
0.05),
and/or
under
conventional
chemotherapy
0.05).
Pre-Omicron
prevented
severe
clinical
courses
variants
cancer.
PBN,
immunodeficiency,
initial
antigens
triggered
only
reduced
responses.
Thus,
subgroups
could
be
identified
for
whom
booster
vaccinations
are
special
significance.
Язык: Английский